Financial News
Press Releases about Clovis Oncology Inc
![](https://www.marketbeat.com/logos/articles/small_20230224080100_analysts-holding-as-pfizer-waits-on-two-phase-3-st.jpg)
![](https://mms.businesswire.com/media/20221211005087/en/305545/22/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20221027005119/en/305545/5/Clovis_Logo_Process_Color.jpg)
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies
November 07, 2022
Exposures
COVID-19
![](https://mms.businesswire.com/media/20221017005267/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20221003005303/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220921005038/en/305545/5/Clovis_Logo_Process_Color.jpg)
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
September 21, 2022
Via Business Wire
![](https://mms.businesswire.com/media/20220911005019/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220808005183/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220720005107/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220606005203/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220614005817/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220505005142/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220504005362/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220428005346/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://www.financialnewsmedia.com/wp-content/uploads/2020/12/BIOV.small_.jpg)
Topics
Intellectual Property
Exposures
Intellectual Property
![](https://mms.businesswire.com/media/20220420005249/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220408005046/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220331005384/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220316005116/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220225005066/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220223005316/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220210005865/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20220110005355/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20211209005139/en/305545/5/Clovis_Logo_Process_Color.jpg)
![](https://mms.businesswire.com/media/20211103005189/en/305545/5/Clovis_Logo_Process_Color.jpg)
Clovis Oncology Announces Third Quarter 2021 Operating Results
November 03, 2021
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.